hVIVO plc (LON:HVO - Get Free Report)'s share price rose 23% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares were traded during trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).
Analyst Ratings Changes
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a report on Friday, May 30th.
View Our Latest Stock Analysis on HVO
hVIVO Stock Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a fifty day moving average price of GBX 15.92 and a two-hundred day moving average price of GBX 17.70. The company has a market cap of £76.07 million, a P/E ratio of 4.43 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
